AMP case report: NGS as the tiebreaker in tumors with similar morphology and equivocal immunophenotype

in 2020 Issues, AMP Case Reports, ARTICLES, May 2020

Test yourself

Here are three questions taken from the case report.
Answers

1. Variants in MED12 are observed in which type of tumors?
a. Leiomyomas
b. Fibroadenomas
c. Phyllodes tumors
d. Leiomyosarcomas
e. All of the above

2. What combination of variants is associated with worse prognosis in thyroid carcinomas?
a. BRAF, TP53
b. TERT, BRAF
c. TP53, TET2
d. HRAS, TP53

3. What do TERT promoter variants do?
a. Increase TERT transcription by generating ETS DNA binding sites.
b. Increase TERT transcription by generating MED12 DNA binding sites.
c. Decrease TERT transcription by generating ETS DNA binding sites.
d. Decrease TERT transcription by generating MED12 DNA binding sites.

1. Variants in MED12 are observed in which type of tumors?
a. Leiomyomas
b. Fibroadenomas
c. Phyllodes tumors
d. Leiomyosarcomas
e. All of the above

2. What combination of variants is associated with worse prognosis in thyroid carcinomas?
a. BRAF, TP53
b. TERT, BRAF
c. TP53, TET2
d. HRAS, TP53

3. What do TERT promoter variants do?
a. Increase TERT transcription by generating ETS DNA binding sites.
b. Increase TERT transcription by generating MED12 DNA binding sites.
c. Decrease TERT transcription by generating ETS DNA binding sites.
d. Decrease TERT transcription by generating MED12 DNA binding sites.

Pages: 1 2